Skip to main content
Top
Published in: Journal of Gastroenterology 10/2014

01-10-2014 | Original Article—Alimentary Tract

Immunoregulatory function of PIR-A/B+ DCs in the inflammatory responses of dextran sodium sulfate-induced colitis

Authors: Akiko Kurishima, Muneo Inaba, Yutaku Sakaguchi, Toshiro Fukui, Kazushige Uchida, Akiyoshi Nishio, Shosaku Nomura, Kazuichi Okazaki

Published in: Journal of Gastroenterology | Issue 10/2014

Login to get access

Abstract

Background

Dendritic cells (DCs) may play an important role in forms of inflammatory bowel disease (IBD), such as Crohn’s disease and ulcerative colitis. DCs are generally recognized as initiators of acquired immunity and also serve as regulators of both innate and acquired immunity. We used the animal model of colitis induced by dextran sodium sulfate (DSS), and examined whether DCs prepared from the colon show immunoregulatory roles in the termination of DSS-induced colitis.

Methods

C57BL/6 mice exposed to DSS for 5 days developed acute colitis. DCs were isolated from the large intestinal lamina propria, and then analyzed for phenotypical, functional, and genetic data.

Results

Only PIR-A/Blow conventional DCs (cDCs) were detected in the steady state. However, after the treatment of DSS, PIR-A/Bhigh cDCs appeared and gradually increased from day 5 to day 7, at which time the DSS-induced colitis was terminated. Then, allogeneic mixed leukocyte reaction (MLR) was performed. The stimulatory activity of PIR-A/Bhigh cDCs obtained on day 7 was very low, and the addition of PIR-A/Bhigh cDCs suppressed the T cell proliferation in MLR, indicating the immunoregulatory role of PIR-A/Bhigh cDCs. The immunoregulatory role of PIR-A/Bhigh cDCs was confirmed by the in vivo transfer experiment, showing their therapeutic effect on DSS-induced colitis. The message level of TGFβi was significantly higher in PIR-A/Bhigh cDCs, while that of IFN-γ was highly upregulated in PIR-A/Blow cDCs, being well in accordance with the fact that PIR-A/Bhigh cDCs showed a suppressive function against activated T cells.

Conclusion

PIR-A/Bhigh cDCs showed a suppressive function against activated T cells by producing inhibitory cytokines.
Literature
1.
go back to reference Shi XZ, Winston JH, Sarna SK. Differential immune and genetic responses in rat models of Crohn’s colitis and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol. 2011;300:G41–51.PubMedCrossRefPubMedCentral Shi XZ, Winston JH, Sarna SK. Differential immune and genetic responses in rat models of Crohn’s colitis and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol. 2011;300:G41–51.PubMedCrossRefPubMedCentral
2.
go back to reference Melger S, Karlsson A, Michaelsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms. Am J Physiol Gastrointest Liver Physiol. 2005;288:G1328–38.CrossRef Melger S, Karlsson A, Michaelsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms. Am J Physiol Gastrointest Liver Physiol. 2005;288:G1328–38.CrossRef
3.
go back to reference Boismenu R, Chen Y. Insight from mouse models of colitis. J Leukoc Biol. 2000;67:267–78.PubMed Boismenu R, Chen Y. Insight from mouse models of colitis. J Leukoc Biol. 2000;67:267–78.PubMed
4.
go back to reference Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990;98:694–702.PubMed Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990;98:694–702.PubMed
5.
go back to reference Whittem CG, Williams AD, Williams CS. Murine colitis modeling using dextran sulfate sodium (DSS). J Vis Exp. 2010;35:pii 1652. Whittem CG, Williams AD, Williams CS. Murine colitis modeling using dextran sulfate sodium (DSS). J Vis Exp. 2010;35:pii 1652.
6.
go back to reference Hochrein H, O’Keeffe M, Luft T, Vandenabeele S, Grumont RJ, Maraskovsky E, et al. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J Exp Med. 2000;192:823–33.PubMedCrossRefPubMedCentral Hochrein H, O’Keeffe M, Luft T, Vandenabeele S, Grumont RJ, Maraskovsky E, et al. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J Exp Med. 2000;192:823–33.PubMedCrossRefPubMedCentral
7.
go back to reference Steinman RM, Hawiger D, Liu K, Bonnyay D, Mahnke K, Iyoda T, et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci. 2003;987:15–25.PubMedCrossRef Steinman RM, Hawiger D, Liu K, Bonnyay D, Mahnke K, Iyoda T, et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci. 2003;987:15–25.PubMedCrossRef
8.
go back to reference Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol. 2006;311:17–56.PubMed Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol. 2006;311:17–56.PubMed
9.
go back to reference Sato K, Yamashita N, Baba M, Matsuyama T. Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood. 2003;101:3581–9.PubMedCrossRef Sato K, Yamashita N, Baba M, Matsuyama T. Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood. 2003;101:3581–9.PubMedCrossRef
10.
go back to reference Fujita S, Sato Y, Sato K, Eizumi K, Fukaya T, Kubo M, et al. Regulatory dendritic cells protect against cutaneous chronic graft-versus-host disease mediated through CD4+ CD25+ Foxp3+ regulatory T cells. Blood. 2007;110:3793–803.PubMedCrossRef Fujita S, Sato Y, Sato K, Eizumi K, Fukaya T, Kubo M, et al. Regulatory dendritic cells protect against cutaneous chronic graft-versus-host disease mediated through CD4+ CD25+ Foxp3+ regulatory T cells. Blood. 2007;110:3793–803.PubMedCrossRef
11.
go back to reference Cho JH, Abraham C. Inflammatory bowel disease genetics: Nod2. Ann Rev Med. 2007;58:410–6.CrossRef Cho JH, Abraham C. Inflammatory bowel disease genetics: Nod2. Ann Rev Med. 2007;58:410–6.CrossRef
12.
go back to reference Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411:599–603.PubMedCrossRef Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411:599–603.PubMedCrossRef
13.
go back to reference Fritz JH, Girardin SE, Fitting C, Werts C, Mengin-Lecreulx D, Caroff M, et al. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur J Immunol. 2005;35:2459–70.PubMedCrossRef Fritz JH, Girardin SE, Fitting C, Werts C, Mengin-Lecreulx D, Caroff M, et al. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur J Immunol. 2005;35:2459–70.PubMedCrossRef
14.
go back to reference Berndt BE, Zhang M, Chen GH, Huffnagle GB, Kao JY. The role of dendritic cells in the development of acute dextran sulfate sodium colitis. J Immunol. 2007;179:6255–62.PubMedCrossRef Berndt BE, Zhang M, Chen GH, Huffnagle GB, Kao JY. The role of dendritic cells in the development of acute dextran sulfate sodium colitis. J Immunol. 2007;179:6255–62.PubMedCrossRef
15.
go back to reference Hoshino S, Inaba M, Iwai H, Ito T, Li M, Gershwin ME, et al. The role of dendritic cell subsets in 2,4,6-trinitrobenzene sulfonic acid-induced ileitis. J Autoimmun. 2010;34:380–9.PubMedCrossRef Hoshino S, Inaba M, Iwai H, Ito T, Li M, Gershwin ME, et al. The role of dendritic cell subsets in 2,4,6-trinitrobenzene sulfonic acid-induced ileitis. J Autoimmun. 2010;34:380–9.PubMedCrossRef
16.
go back to reference Hoshino S, Kurishima A, Inaba M, Ando Y, Fukui T, Uchida K, et al. Amelioration of 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice by immunoregulatory dendritic cells. J Gastroenterol. 2011;46:1368–81.PubMedCrossRef Hoshino S, Kurishima A, Inaba M, Ando Y, Fukui T, Uchida K, et al. Amelioration of 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice by immunoregulatory dendritic cells. J Gastroenterol. 2011;46:1368–81.PubMedCrossRef
17.
go back to reference Nakano H, Yanagita M, Gunn MD. CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med. 2001;194:1171–8.PubMedCrossRefPubMedCentral Nakano H, Yanagita M, Gunn MD. CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med. 2001;194:1171–8.PubMedCrossRefPubMedCentral
18.
go back to reference Coombes JL, Siddiqui KR, Arancibia-Cárcamo CV, Hall J, Sun CM, Belkaid Y, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-β and retinoic acid-dependent mechanism. J Exp Med. 2007;204:1757–64.PubMedCrossRefPubMedCentral Coombes JL, Siddiqui KR, Arancibia-Cárcamo CV, Hall J, Sun CM, Belkaid Y, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-β and retinoic acid-dependent mechanism. J Exp Med. 2007;204:1757–64.PubMedCrossRefPubMedCentral
19.
go back to reference Danese S. Nonimmune cells in inflammatory bowel disease: from victim to villain. Trends Immunol. 2008;29:555–64.PubMedCrossRef Danese S. Nonimmune cells in inflammatory bowel disease: from victim to villain. Trends Immunol. 2008;29:555–64.PubMedCrossRef
21.
go back to reference Abe K, Nguyen KP, Fine SD, Mo JH, Shen C, Shenouda S, et al. Conventional dendritic cells regulate the outcome of colonic inflammation independently of T cells. Proc Natl Acad Sci USA. 2007;104:17022–7.PubMedCrossRefPubMedCentral Abe K, Nguyen KP, Fine SD, Mo JH, Shen C, Shenouda S, et al. Conventional dendritic cells regulate the outcome of colonic inflammation independently of T cells. Proc Natl Acad Sci USA. 2007;104:17022–7.PubMedCrossRefPubMedCentral
22.
go back to reference Fahlén L, Read S, Gorelik L, Hurst SD, Coffman RL, Flavell RA, et al. T cells that cannot respond to TGF-β escape control by CD4+ CD25+ regulatory T cells. J Exp Med. 2005;201:737–46.PubMedCrossRefPubMedCentral Fahlén L, Read S, Gorelik L, Hurst SD, Coffman RL, Flavell RA, et al. T cells that cannot respond to TGF-β escape control by CD4+ CD25+ regulatory T cells. J Exp Med. 2005;201:737–46.PubMedCrossRefPubMedCentral
23.
go back to reference Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389:737–42.PubMedCrossRef Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389:737–42.PubMedCrossRef
24.
go back to reference Matteoli G, Mazzini E, Iliev ID, Mileti E, Fallarino F, Puccetti P, et al. Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. Gut. 2010;59:595–604.PubMedCrossRef Matteoli G, Mazzini E, Iliev ID, Mileti E, Fallarino F, Puccetti P, et al. Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. Gut. 2010;59:595–604.PubMedCrossRef
25.
go back to reference Suri-Payer E, Cantor H. Differential cytokine requirements for regulation of autoimmune gastritis and colitis by CD4+ CD25+ T cells. J Autoimmun. 2001;16:115–23.PubMedCrossRef Suri-Payer E, Cantor H. Differential cytokine requirements for regulation of autoimmune gastritis and colitis by CD4+ CD25+ T cells. J Autoimmun. 2001;16:115–23.PubMedCrossRef
26.
go back to reference Bilsborough J, George TC, Norment A, Viney JL. Mucosal CD8alpha+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology. 2003;108:481–92.PubMedCrossRefPubMedCentral Bilsborough J, George TC, Norment A, Viney JL. Mucosal CD8alpha+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology. 2003;108:481–92.PubMedCrossRefPubMedCentral
27.
go back to reference Kubagawa H, Burrows PD, Cooper MD. A novel pair of immunoglobulin-like receptors expressed by B cells and myeloid cells. Proc Natl Acad Sci USA. 1997;94:5261–6.PubMedCrossRefPubMedCentral Kubagawa H, Burrows PD, Cooper MD. A novel pair of immunoglobulin-like receptors expressed by B cells and myeloid cells. Proc Natl Acad Sci USA. 1997;94:5261–6.PubMedCrossRefPubMedCentral
28.
go back to reference Hayami K, Fukuta D, Nishikawa Y, Yamashita Y, Inui M, Ohyama Y, et al. Molecular cloning of a novel murine cell-surface glycoprotein homologous to killer cell inhibitory receptors. J Biol Chem. 1997;272:7320–7.PubMedCrossRef Hayami K, Fukuta D, Nishikawa Y, Yamashita Y, Inui M, Ohyama Y, et al. Molecular cloning of a novel murine cell-surface glycoprotein homologous to killer cell inhibitory receptors. J Biol Chem. 1997;272:7320–7.PubMedCrossRef
29.
go back to reference Ujike A, Takeda K, Nakamura A, Ebihara S, Akiyama K, Takai T. Impaired dendritic cell maturation and increased TH2 responses in PIR-B−/− mice. Nat Immunol. 2002;3:542–8.PubMedCrossRef Ujike A, Takeda K, Nakamura A, Ebihara S, Akiyama K, Takai T. Impaired dendritic cell maturation and increased TH2 responses in PIR-B−/− mice. Nat Immunol. 2002;3:542–8.PubMedCrossRef
30.
go back to reference Castro-Sánchez P, Martín-Villa JM. Gut immune system and oral tolerance. Br J Nutr. 2013;109(Suppl 2):S3–11.PubMedCrossRef Castro-Sánchez P, Martín-Villa JM. Gut immune system and oral tolerance. Br J Nutr. 2013;109(Suppl 2):S3–11.PubMedCrossRef
31.
go back to reference Kaser A, Ludwiczek O, Holzmann S, Moschen AR, Weiss G, Enrich B, et al. Increased expression of CCL20 in human inflammatory bowel disease. J Clin Immunol. 2004;24:74–85.PubMedCrossRef Kaser A, Ludwiczek O, Holzmann S, Moschen AR, Weiss G, Enrich B, et al. Increased expression of CCL20 in human inflammatory bowel disease. J Clin Immunol. 2004;24:74–85.PubMedCrossRef
32.
go back to reference Hruz P, Eckmann L. Innate immune defence: NOD2 and autophagy in the pathogenesis of Crohn’s disease. Swiss Med Wkly. 2010;140:w13135.PubMed Hruz P, Eckmann L. Innate immune defence: NOD2 and autophagy in the pathogenesis of Crohn’s disease. Swiss Med Wkly. 2010;140:w13135.PubMed
33.
go back to reference Man SK, Kaakoush NO, Mitcell HM. The role of bacteria and pattern-recognition receptors in Crohn’s disease. Nat Rev Gastroenterol Hepatol. 2011;8:152–68.PubMedCrossRef Man SK, Kaakoush NO, Mitcell HM. The role of bacteria and pattern-recognition receptors in Crohn’s disease. Nat Rev Gastroenterol Hepatol. 2011;8:152–68.PubMedCrossRef
34.
go back to reference Ardizzone S, Cassinotti A, Manes G, Porro GB. Immunomodulators for all patients with inflammatory bowel disease? Ther Adv Gastroenterol. 2010;3:31–42.CrossRef Ardizzone S, Cassinotti A, Manes G, Porro GB. Immunomodulators for all patients with inflammatory bowel disease? Ther Adv Gastroenterol. 2010;3:31–42.CrossRef
35.
go back to reference Fiorino G, Szabò H, Fries W, Malesci A, Peyrin-Biroulet L, Danese S. Adalimumab in Crohn’s disease: tips and tricks after 5 years of clinical experience. Curr Med Chem. 2011;18:1230–8.PubMedCrossRef Fiorino G, Szabò H, Fries W, Malesci A, Peyrin-Biroulet L, Danese S. Adalimumab in Crohn’s disease: tips and tricks after 5 years of clinical experience. Curr Med Chem. 2011;18:1230–8.PubMedCrossRef
36.
go back to reference Nielsen OH, Seidelin JB, Munck LK, Rogler G. Use of biological molecules in the treatment of inflammatory bowel disease. J Intern Med. 2011;2011(270):15–28.CrossRef Nielsen OH, Seidelin JB, Munck LK, Rogler G. Use of biological molecules in the treatment of inflammatory bowel disease. J Intern Med. 2011;2011(270):15–28.CrossRef
37.
go back to reference Scherl EJ, Kumar S, Warren RU. Review of the safety and efficacy of ustekinumab. Ther Adv Gastroenterol. 2010;3:321–8.CrossRef Scherl EJ, Kumar S, Warren RU. Review of the safety and efficacy of ustekinumab. Ther Adv Gastroenterol. 2010;3:321–8.CrossRef
38.
go back to reference Ghosh S, Panaccione R. Anti-adhesion molecule therapy for inflammatory bowel disease. Ther Adv Gastroenterol. 2010;3:239–58.CrossRef Ghosh S, Panaccione R. Anti-adhesion molecule therapy for inflammatory bowel disease. Ther Adv Gastroenterol. 2010;3:239–58.CrossRef
Metadata
Title
Immunoregulatory function of PIR-A/B+ DCs in the inflammatory responses of dextran sodium sulfate-induced colitis
Authors
Akiko Kurishima
Muneo Inaba
Yutaku Sakaguchi
Toshiro Fukui
Kazushige Uchida
Akiyoshi Nishio
Shosaku Nomura
Kazuichi Okazaki
Publication date
01-10-2014
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 10/2014
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-013-0879-x

Other articles of this Issue 10/2014

Journal of Gastroenterology 10/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine